Turk Onkoloji Dergisi-Turkish Journal of Oncology

metrics 2024

Innovating cancer care with rigorous research and peer-reviewed insights.

Introduction

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

Metrics 2024

SCIMAGO Journal Rank0.14
Journal Impact Factor0.30
Journal Impact Factor (5 years)0.20
H-Index9
Journal IF Without Self0.30
Eigen Factor0.00
Normal Eigen Factor0.03
Influence0.05
Immediacy Index0.10
Cited Half Life4.00
Citing Half Life9.30
JCI0.05
Total Documents743
WOS Total Citations115
SCIMAGO Total Citations258
SCIMAGO SELF Citations32
Scopus Journal Rank0.14
Cites / Document (2 Years)0.26
Cites / Document (3 Years)0.26
Cites / Document (4 Years)0.27

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #344/404
Percentile 14.85
Quartile Q4

IF (Web Of Science)

ONCOLOGY
Rank 309/322
Percentile 4.20
Quartile Q4

JCI (Web Of Science)

ONCOLOGY
Rank 314/322
Percentile 2.48
Quartile Q4

Quartile History

Similar Journals

Translational Lung Cancer Research

Pioneering breakthroughs in oncology and lung cancer treatment.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Journal of the Egyptian National Cancer Institute

Bridging gaps in cancer knowledge for a healthier tomorrow.
Publisher: SPRINGERISSN: 1110-0362Frequency: 1 issue/year

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

ANNALS OF ONCOLOGY

Innovating therapies for a brighter tomorrow.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Translational Oncology

Bridging Research and Patient Care in Oncology
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Radiation Oncology

Transforming cancer treatment with cutting-edge radiation studies.
Publisher: BMCISSN: Frequency: 1 issue/year

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Wspolczesna Onkologia-Contemporary Oncology

Elevating Standards in Cancer Research and Treatment
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1428-2526Frequency: 4 issues/year

Wspolczesna Onkologia - Contemporary Oncology is a leading open-access journal dedicated to the field of oncology and radiology, published by TERMEDIA PUBLISHING HOUSE LTD since 1999. With its ISSN 1428-2526 and E-ISSN 1897-4309, the journal has established a prominent place in scholarly publishing, contributing significantly to the advancement of cancer research and treatment modalities. Located in Poznań, Poland, it operates within a framework of high academic standards, currently holding a Q3 quartile ranking in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging for the year 2023. The journal serves as a valuable resource for researchers, medical professionals, and students alike, providing a platform for innovative studies and reviews that drive the clinical application of oncological practices. With its commitment to open access, Wspolczesna Onkologia allows for widespread dissemination of knowledge, ensuring that cutting-edge research is accessible to a global audience, thus bridging gaps in cancer care and fostering collaborative advancements in the field.

Practical Radiation Oncology

Connecting Research with Real-World Applications
Publisher: ELSEVIER SCIENCE INCISSN: 1879-8500Frequency: 6 issues/year

Practical Radiation Oncology is a premier journal published by Elsevier Science Inc., focusing on the critically important fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1879-8500, this journal serves as an essential resource for professionals and researchers dedicated to advancing the practice and research of radiation oncology. Established in 2011 and continuing through 2024, it has quickly gained recognition, achieving a prestigious Q2 ranking in Oncology and an exceptional Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. The journal, housed in New York, USA, provides a platform for innovative research and practical insights, aimed at enhancing therapeutic practices and improving patient outcomes. As part of its commitment to fostering scientific dialogue, it also features a range of articles, reviews, and clinical studies that cater to the diverse interests of its readers. Hard-copy availability combined with digital access ensures a broad reach for the latest advancements in the field.

Oncology Letters

Empowering Oncology with Groundbreaking Discoveries
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

World Journal of Gastrointestinal Oncology

Bridging the gap between research and clinical application in gastrointestinal health.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.